MASHINIi

Krystal Biotech, Inc..

KRYS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Krystal Biotech, Inc. is a commercial-stage gene therapy company focused on developing and commercializing novel treatments for dermatological diseases. The company's lead product is VYJUVEK™ (beremagene geperpavec), a gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB). They ut...Show More

Ethical Profile

Mixed.

Krystal Biotech's core mission involves developing gene therapies for rare diseases like dystrophic epidermolysis bullosa (VYJUVEK), aiming to meet high medical needs. The company supports patient access through a $0 co-pay program for commercially insured individuals and a Patient Assistance Program offering up to $15,000 for uninsured/underinsured patients. However, the CEO to median employee pay ratio was 66:1 in 2024 ($15.6 million vs. $235,125), and employee reviews on compensation are reportedly mixed. Transparency is limited in areas like price accessibility, ethical sourcing, and environmental impact, with specific data largely unavailable.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect10
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-60
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products-50
-100100

Better Health for All

0

No specific, concrete evidence was found in the provided articles to assess Krystal Biotech against any of the 'Better Health for All' KPIs. The articles either discuss other companies, or, in the case of Krystal Biotech's pipeline, explicitly state that no specific health outcomes, clinical data, safety data, pricing information, or other relevant metrics are provided.

1

Fair Money & Economic Opportunity

0

Krystal Biotech, Inc. is a gene therapy company focused on developing and commercializing treatments for rare diseases, not a financial institution.

1
Its core business does not involve lending, insuring, moving, or storing money. Therefore, the company does not offer consumer credit products, generate revenue from high-cost financial products, or manage customer financial data. While the company provides patient assistance programs and aims for broad access to its medical treatments, these activities do not align with the rubric's definition of financial inclusion initiatives, fair lending practices, or wealth-building outcomes for underserved populations in a financial context.
2
The company's educational efforts focus on rare diseases and treatments, not general financial literacy.
3
Product simplicity relates to the ease of administering medical treatments, not the clarity of financial product disclosures.
4
As such, all KPIs under 'Fair Money & Economic Opportunity' are not applicable to Krystal Biotech's operations.

Fair Pay & Worker Respect

10

For fiscal year 2024, the CEO total compensation to median employee compensation ratio was 66:1.

1
No other specific, quantifiable data points were provided for the remaining KPIs related to fair pay and worker respect.

Fair Trade & Ethical Sourcing

0

The provided articles do not contain specific, quantitative data for any of the KPIs related to Fair Trade & Ethical Sourcing.

1
Information regarding fair-trade certification, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend is not available.
2
The documents primarily focus on corporate governance guidelines and internal compliance programs, without detailing external sourcing practices or supply chain metrics.
3

Honest & Fair Business

0

No evidence available to assess Krystal Biotech, Inc. on Honest & Fair Business.

Kind to Animals

-60

Krystal Biotech utilizes alternative testing methods, such as patient-derived cells and organoids, for product candidates like KB407.

1
However, the same product, KB407, was also tested in mice and nonhuman primates, with an ongoing study involving 40 nonhuman primates, indicating that alternative assays are used sporadically while animal tests remain prevalent.
2
The company conducts preclinical laboratory tests and in vivo studies in accordance with FDA’s Good Laboratory Practice (GLP) regulations and applicable requirements for the humane use of laboratory animals.
3
This suggests a policy that exists but is vague, as it focuses on regulatory compliance rather than a clear commitment to reducing or eliminating animal testing.

No War, No Weapons

0

No evidence available to assess Krystal Biotech, Inc. on No War, No Weapons.

Planet-Friendly Business

0

No specific, concrete data points were found across the provided articles for any of the Planet-Friendly Business KPIs. The articles primarily consist of general company information, ESG risk ratings (such as S&P Global ESG Score of 20 and Sustainalytics ESG risk rating of 32.7), or explicit statements that no relevant data was found for the specified environmental performance indicators.

1

Respect for Cultures & Communities

0

No specific, concrete evidence was found in the provided articles to assess Krystal Biotech, Inc. against the defined KPIs for 'Respect for Cultures & Communities'.

1
The articles either discuss other companies, general industry trends, or financial performance without providing actionable data points for Krystal Biotech's engagement with local or indigenous communities, cultural preservation, or related practices.
2

Safe & Smart Tech

0

No evidence available to assess Krystal Biotech, Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

-50

Krystal Biotech contracts with third parties for the disposal of various biologic, chemical, and radioactive substances and wastes generated by its operations, and is subject to federal and state environmental protection laws, which aligns with industry standard practices.

1
The company is cooperating with subpoenas from the U.S. Department of Justice regarding its sponsored genetic testing program and commercial practices, indicating potential waste disposal violations.
2
For its VYJUVEK product, Krystal Biotech utilizes CSafe's Retest & Reuse program for shipping, which involves reusable shippers and reduces avoidable landfill waste, representing one small-scale waste reduction initiative.
3
The company provides disposal instructions for used VYJUVEK bandages, advising disinfection and placement in sealed plastic bags for household waste.
4

Own Krystal Biotech, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.